What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Kim N. Chi mainly investigates Prostate cancer, Internal medicine, Surgery, Oncology and Docetaxel.
His studies in Prostate cancer integrate themes in fields like Cancer research and Urology.
His Urology study incorporates themes from Interim analysis, Cabazitaxel, Androgen deprivation therapy, Placebo and Prednisone.
His study looks at the relationship between Internal medicine and fields such as Endocrinology, as well as how they intersect with chemical problems.
His work on Retrospective cohort study and Survival rate as part of general Surgery study is frequently linked to Spinal cord compression, Denosumab and Bone Density Conservation Agents, therefore connecting diverse disciplines of science.
His Oncology study deals with Hazard ratio intersecting with Cohort.
His most cited work include:
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer (4473 citations)
- Abiraterone and Increased Survival in Metastatic Prostate Cancer (3027 citations)
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy (2853 citations)
What are the main themes of his work throughout his whole career to date?
Kim N. Chi mainly focuses on Prostate cancer, Internal medicine, Oncology, Docetaxel and Cancer research.
His study ties his expertise on Prednisone together with the subject of Prostate cancer.
His Internal medicine study typically links adjacent topics like Surgery.
His work carried out in the field of Oncology brings together such families of science as Clinical trial, Abiraterone, Androgen deprivation therapy, Hazard ratio and Prostate-specific antigen.
The Docetaxel study combines topics in areas such as Cabazitaxel, Mitoxantrone, Urology, Randomized controlled trial and Placebo.
His Cancer research research includes themes of Prostate, Apoptosis, Clusterin, Immunology and Circulating tumor DNA.
He most often published in these fields:
- Prostate cancer (74.19%)
- Internal medicine (63.38%)
- Oncology (53.32%)
What were the highlights of his more recent work (between 2017-2021)?
- Prostate cancer (74.19%)
- Internal medicine (63.38%)
- Oncology (53.32%)
In recent papers he was focusing on the following fields of study:
His main research concerns Prostate cancer, Internal medicine, Oncology, Cancer research and Castration resistant.
His Prostate cancer study combines topics in areas such as Clinical trial, Disease and Prednisone.
His Prednisone research incorporates themes from Abiraterone acetate and Adverse effect.
His work on Enzalutamide, Docetaxel, Androgen deprivation therapy and Phases of clinical research is typically connected to In patient as part of general Internal medicine study, connecting several disciplines of science.
Kim N. Chi interconnects Cancer, Chemotherapy, Proportional hazards model, Hazard ratio and Cohort in the investigation of issues within Oncology.
His Cancer research research includes elements of Cell, Somatic cell, DNA repair, Germ cell and Circulating tumor DNA.
Between 2017 and 2021, his most popular works were:
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer (283 citations)
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. (273 citations)
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. (223 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Kim N. Chi mainly investigates Prostate cancer, Internal medicine, Oncology, Cancer research and Enzalutamide.
His Prostate cancer research is multidisciplinary, incorporating elements of Clinical trial, Prednisone and Docetaxel.
His research integrates issues of Febrile neutropenia, Placebo and Apalutamide in his study of Docetaxel.
His Apalutamide study incorporates themes from Interim analysis, Darolutamide and Urology.
His research integrates issues of Liquid biopsy, Cancer, Prostate, Circulating tumor DNA and Cohort in his study of Oncology.
His work deals with themes such as Abiraterone and Olaparib, which intersect with Enzalutamide.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
